Skip to main content
Clinical Trials/NCT03380858
NCT03380858
Unknown
Not Applicable

REINFORCEMENT ANASTOMOSIS IN ONCOLOGIC COLORECTAL SURGERY

National Cancer Institute, Naples1 site in 1 country390 target enrollmentStarted: November 2, 2017Last updated:

Overview

Phase
Not Applicable
Sponsor
National Cancer Institute, Naples
Enrollment
390
Locations
1
Primary Endpoint
fistula incidence

Overview

Brief Summary

In colorectal surgery about 30% of postoperative mortality is attributed to anastomotic leak, whit an incidence range between 1.8% and 15.9%. Preventing the anastomotic leak can therefore bring benefits to the patient and the health system. To date we have technologically advanced suturizers and the correct realization (well-vascularized margins, not in tension, etc.) remains crucial to prevent anastomotic dehiscence. Experimental results demonstrate that modified cyanacrylate is a suitable potential "reinforcement" on intestinal anastomoses (manual or linear intra-corporeal). Applied after mechanical anastomosis, it polymerizes in a short time, closing the spaces of the suture line between one point and the other, expressing an adhesive, hemostatic and sealing action on the tissues, also creating an effective antiseptic barrier towards of the most common infectious or pathogenic agents.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Informed consent
  • patients undergoing to oncologic colorectal surgery with colorectal anastomosis

Exclusion Criteria

  • refuse informed consent
  • patients undergoing to oncologic colorectal surgery without colorectal anastomosis

Outcomes

Primary Outcomes

fistula incidence

Time Frame: From day of surgery up to 30 postoperative days

Secondary Outcomes

  • infection(From day of surgery up to 30 postoperative days)
  • anastomitic bleeding(From day of surgery up to 30 postoperative days)

Investigators

Sponsor
National Cancer Institute, Naples
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Daniela Rega

doctor

National Cancer Institute, Naples

Study Sites (1)

Loading locations...

Similar Trials